Moshmi Bhattacharya is an Associate Professor of Medicine at the Department of Medicine, Division of Endocrinology, Metabolism & Nutrition, at Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA. Before joining Rutgers University, she was an Associate Professor in the Departments of Physiology and Pharmacology, and Oncology at Western University, in London, Ontario, Canada. She received her B.Sc. Degree in Natural Sciences at the University of the West Indies, St Augustine, Trinidad, West Indies in 1994. She did her Ph.D. in the Department of Pharmacology & Therapeutics at McGill University, Montreal, Canada, from 1996 to 2000, followed by postdoctoral studies at the Robarts Research Institute in Ontario from 2001 to 2004. Her research interests are focused on understanding the molecular mechanisms by which G protein-coupled receptors (GPCRs), targets of 34% of all pharmaceutical drugs, regulate health and disease. Currently, her laboratory studies how signaling of the kisspeptin receptor, a GPCR, regulates diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) and liver cancer. MASLD impacts over one billion individuals globally and is a leading cause of liver cancer (hepatocellular carcinoma). These translational, multidisciplinary studies are conducted using various pre-clinical and clinical models.
Moshmi Bhattacharya is an Associate Professor of Medicine at the Department of Medicine, Division of Endocrinology, Metabolism & Nutrition, at Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA. Before joining Rutgers University, she was an Associate Professor in the Departments of Physiology and Pharmacology, and Oncology at Western University, in London, Ontario, Canada. She received her B.Sc. Degree in Natural Sciences at the University of the West Indies, St Augustine, Trinidad, West Indies in 1994. She did her Ph.D. in the Department of Pharmacology & Therapeutics at McGill University, Montreal, Canada, from 1996 to 2000, followed by postdoctoral studies at the Robarts Research Institute in Ontario from 2001 to 2004. Her research interests are focused on understanding the molecular mechanisms by which G protein-coupled receptors (GPCRs), targets of 34% of all pharmaceutical drugs, regulate health and disease. Currently, her laboratory studies how signaling of the kisspeptin receptor, a GPCR, regulates diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) and liver cancer. MASLD impacts over one billion individuals globally and is a leading cause of liver cancer (hepatocellular carcinoma). These translational, multidisciplinary studies are conducted using various pre-clinical and clinical models.